Immunization with Recombinant Accessory Protein-Deficient SARS-CoV-2 Protects against Lethal Challenge and Viral Transmission
Abstract
Live-attenuated vaccines (LAVs) are able to induce robust immune responses, including both humoral and cellular immunity, representing a very promising option to provide broad and long-term immunity. To develop LAVs for SARS-CoV-2, we engineered attenuated recombinant SARS-CoV-2 (rSARS-CoV-2) that simultaneously lacks the viral open reading frame 3a (ORF3a) in combination with either ORF6, ORF7a, or ORF7b (Δ3a/Δ6, Δ3a/Δ7a, and Δ3a/Δ7b, respectively) proteins.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 15, 2023
- Source ID
- 10.1128/spectrum.00653-23
Entities
People
- Amit Kapoor
- Andreu Garcia-vilanova
- Anna Allué-guardia
- Chengjin Ye
- James J. Kobie
- Jordi B. Torrelles
- Jun-gyu Park
- Kevin Chiem
- Luis Martinez-Sobrido
- Mark R. Walter
- Paula Pino Tamayo
- Piyush Dravid
- Richard K Plemper
- Vinay Shivanna
Organizations
- Georgia State University
- Texas Biomedical Research Institute
- University of Alabama at Birmingham